Immunovant IMVT
NASDAQ IMVT
$33.99 +0.34 (+1.01%)
As of: Oct 2, 2026 · 10:51 AM EDT

Immunovant (IMVT) Return on Assets [ROA] (2019 - 2026)

Updated

Immunovant's Return on Assets [ROA] was -59.49% in fiscal Q1 2027 (quarter ended Jun 30, 2026), up 2.74 percentage points from -62.23% a year earlier but down 9.16 percentage points from the prior quarter.

Analysis

Immunovant (IMVT) Return on Assets [ROA] (2019 - 2026) Analysis & Trends

For FY2026 (ended Mar 31, 2026), Return on Assets [ROA] at Immunovant came in at -58.34%, down 0.97 percentage points from FY2025.

  • Return on Assets [ROA] has now declined for four consecutive fiscal years, with a five-year change of -17.17 percentage points (FY2021 to FY2026).
  • In earlier fiscal years, Return on Assets [ROA] was -57.37% in FY2025 (-9.00 pp), -48.37% in FY2024 (-2.58 pp), -45.79% in FY2023 (-12.01 pp) and -33.78% in FY2022 (+7.39 pp).
  • Quarterly Return on Assets [ROA] has moved between -81.72% (fiscal Q3 2025) and -24.82% (fiscal Q3 2022) over five years.
  • Compared with a year earlier, Return on Assets [ROA] has increased for three straight quarters, with an average year-over-year change of -4.04 percentage points over the last eight quarters.
  • The best year-over-year quarter for Return on Assets [ROA] over five years was fiscal Q3 2026 (a gain of 24.95 percentage points); the worst was fiscal Q2 2024 (a drop of 39.47 percentage points).
  • Per Business Quant data, IMVT's Return on Assets [ROA] in the three fiscal quarters before Q1 2027 was -50.32% (Q4 2026), -56.77% (Q3 2026) and -74.68% (Q2 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 10.47%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 4.65%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 2.45%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 28.37%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 9.10%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 9.29%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -6.13%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 2.14%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 16.34%
10 Immunovant 6.97 Bn 6.97 Bn - -59.49%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -59.49%
Mar 31, 2026 -50.32%
Dec 31, 2025 -56.77%
Sep 30, 2025 -74.68%
Jun 30, 2025 -62.23%
Mar 31, 2025 -69.14%
Dec 31, 2024 -81.72%
Sep 30, 2024 -58.44%
Jun 30, 2024 -43.40%
Mar 31, 2024 -37.64%
Dec 31, 2023 -48.52%
Sep 30, 2023 -79.36%
Jun 30, 2023 -64.60%
Mar 31, 2023 -48.94%
Dec 31, 2022 -44.93%
Sep 30, 2022 -39.89%
Jun 30, 2022 -34.21%
Mar 31, 2022 -29.61%
Dec 31, 2021 -24.82%
Sep 30, 2021 -26.84%
API Access

Immunovant Return on Assets [ROA] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=IMVT&period=max&api_key=YOUR_API_KEY